Alrabadi Nasr, Jarrah Mohamad Ismail, Alzoubi Karem Hasan
Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
Department of Internal Medicine, Interventional Cardiology Division, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
Biomed Rep. 2020 Sep;13(3):14. doi: 10.3892/br.2020.1321. Epub 2020 Jun 26.
The association between ischemic heart disease (IHD) and the concurrent use of anabolic androgenic steroids (AASs) is underestimated in clinical settings. The tendency of patients to not disclose AASs use may explain this underestimation. In the present case report, the clinical case of a 26-year-old physically active male, who was a physician, without any classical coronary risk factors, who presented with chest pain that was misdiagnosed by the peripheral care unit as skeletal muscle pain is described. Later, the patient was brought to our central hospital (King Abdullah University Hospital) suffering from a massive acute myocardial infarction with marked ECG changes and cardiogenic shock. Following stabilization of his condition, a detailed history of the patient was taken, during which the patient admitted that he was a chronic user of the anabolic steroid sustanon (250 mg, once/week for 6 months) and amino acid supplements (whey protein isolate, 6 tabs every day for 1 year). Specific cardiac markers were increased and the patient exhibited dynamic ischemic changes in his electrocardiogram. Notably, the coronary angiogram of the patient demonstrated ostial occlusion of the left anterior descending artery, which was associated with mid-right coronary artery embolic obstruction. Other than the anabolic steroids and protein supplementation use, the patient history, examination and lab evaluation were normal. During follow up, the patient continued to suffer heart failure with low ejection fraction. In addition, he developed apical thrombus 2 months after primary admission. The patient developed tachycardia in spite of optimal medical treatment and finally received an implantable cardioverter defibrillator. Physicians should always be aware of the possibility of AASs use in young physically active patients. IHD should always be suspected and investigated with typical chest pain in healthy young patients, even if regular risk factors are not present. Medical professionals should not be excluded as potential AASs users/abusers.
在临床环境中,缺血性心脏病(IHD)与合成代谢雄激素类固醇(AASs)同时使用之间的关联被低估了。患者不透露使用AASs的倾向可能解释了这种低估情况。在本病例报告中,描述了一名26岁身体活跃的男性医生的临床病例,他没有任何经典的冠状动脉危险因素,因胸痛就诊,外周护理单元将其误诊为骨骼肌疼痛。后来,该患者被送往我们的中心医院(阿卜杜拉国王大学医院),患有大面积急性心肌梗死,伴有明显的心电图变化和心源性休克。在其病情稳定后,对患者进行了详细的病史询问,期间患者承认自己长期使用合成代谢类固醇十一酸睾酮(250毫克,每周一次,持续6个月)和氨基酸补充剂(乳清蛋白分离物,每天6片,持续1年)。特定的心脏标志物升高,患者心电图显示动态缺血变化。值得注意的是,患者的冠状动脉造影显示左前降支动脉开口闭塞,并伴有右冠状动脉中段栓塞性阻塞。除了使用合成代谢类固醇和蛋白质补充剂外,患者的病史、检查和实验室评估均正常。在随访期间,患者持续患有射血分数低的心力衰竭。此外,在初次入院2个月后,他出现了心尖血栓。尽管接受了最佳药物治疗,患者仍出现心动过速,最终接受了植入式心脏复律除颤器。医生应始终意识到年轻身体活跃患者使用AASs的可能性。对于健康的年轻患者,即使不存在常规危险因素,出现典型胸痛时也应始终怀疑并调查是否患有IHD。医疗专业人员不应被排除在潜在的AASs使用者/滥用者之外。